Skip to main content
SpringerLink
Log in

Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1

  • Original Papers
  • Published:
Archives of Virology Aims and scope Submit manuscript

Summary

We have sequentially passaged both laboratory and clinical isolates of the human immunodeficiency virus type 1 (HIV-1) in MT-4 cells in the presence of increasing concentrations of different drugs to derive viral variants that are multiply resistant to various combinations of ddC, ddI, d4T and AZT. The EC50 values obtained for the viruses thus generated varied between 50–100 times above those of parental wild-type strains in the case of AZT, 20–30 times for d4T, but only 10–15 times for ddI and ddC. Cultivation of AZT-resistant viruses in the presence of increasing concentrations of ddI yielded viruses that were resistant to the latter compound, with no apparent decrease in susceptibility to AZT. Sometimes, viruses selected for resistance against ddI were cross-resistant as well against ddC, although most viruses selected for resistance to ddC were not cross-resistant to ddI. Combinations of two or three of these compounds inhibited replication of HIV variants that displayed resistance to the same drugs when tested individually. No emergence of drug resistance was demonstrable when combinations of drugs were employed simultaneously in these selection protocols or when single drugs were used in concert with interferon-2α or high dilutions of virus-neutralizing antisera. Cloning and sequencing of some viruses resistant to each of AZT, ddI, and ddC revealed the simultaneous presence of mutations at sites 41, 74, 184 and 215 within the HIV pol gene open reading frame.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boucher CAB, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J, Larder BA (1992) Ordered appearance of zidovudine resistance mutation during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 246: 1155–1158

    Google Scholar 

  2. Boulerice F, Bour S, Geleziunas R, Lvovich A, Wainberg MA (1990) High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol 64: 1745–1755

    PubMed  Google Scholar 

  3. Dornsife RE, Clair MH, Huang AT, Panella TJ, Koszalka GW, Burns CL, Averett DR (1991) Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother 35: 322–328

    PubMed  Google Scholar 

  4. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildan D, Schooley RT, Jackson GG, Durack DT, King D, The AZT Collaborative Working Group (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 317: 185–191

    PubMed  Google Scholar 

  5. Gao Q, Gu Z, Parniak MA, Li X, Wainberg MA (1992) In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J Virol 66: 12–19

    PubMed  Google Scholar 

  6. Gao Q, Parniak M, Gu Z, Wainberg MA (1992) Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of either AZT or ddI but not combinations of the same drugs. Leukemia 6: 192S-195S

    PubMed  Google Scholar 

  7. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA (1993) The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 37: 1390–1392

    PubMed  Google Scholar 

  8. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA (1992) Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 66: 7128–7135

    PubMed  Google Scholar 

  9. Jackson GG, Paul DA, Falk LA, Rubenis M, Despotes JC, Mack D, Knigge M, Emeson EE (1988) Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and effects of treatment with zidovudine (AZT). Ann Intern Med 108: 175–181

    PubMed  Google Scholar 

  10. Johnson VA, Barlow MA, Merrill DP, Chou TC, Hirsch MS (1990) Three-drug synergistic inhibition of HIV-1 replication in vitro by azidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis 161: 1059–1067

    PubMed  Google Scholar 

  11. Johnson VA, Merrill DP, Videler JA, Chou T-C, Byington RE, Eron JJ, D'Aquila RT, Hirsch MS (1991) Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 164: 646–655

    PubMed  Google Scholar 

  12. Kellam P, Boucher CAB, Larder BA (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 89: 1934–1938

    PubMed  Google Scholar 

  13. Larder BA, Kellam P, Kemp SD (1993) Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365: 451–453

    PubMed  Google Scholar 

  14. Larder BA, Kemp SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 46: 1155–1157

    Google Scholar 

  15. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Qointero JC, Hoffman JM, Emini EA, Colman ME (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 65: 4887–4892

    PubMed  Google Scholar 

  16. Richman DD, Grimes JM, Lagkos SW (1991) Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 3: 743–746

    Google Scholar 

  17. Richman D, Shih C-K, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 88: 1241–1245

    Google Scholar 

  18. Roberts JD, Bebenk K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171–1173

    PubMed  Google Scholar 

  19. Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao X-J, Fanning M, Montaner JSG, O'Shaughnessy M, Gelmon K, Tsoukas C, Gill J, Ruedy J, Wainberg MA, The Canadian Zidovudine Multi-Centre Study Group (1989) Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine (AZT) therapy. AIDS 3: 411–415

    PubMed  Google Scholar 

  20. Schinazi RF, Lloyd RM Jr, Nguyen M-H, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW (1993) Characterization of human immunodeficiency viruses resistant to oxothiolane-cytosine nucleosides. Antimicrob Agents Chemother 37: 875–881

    PubMed  Google Scholar 

  21. Smith MS, Koerber KL, Pagano JS (1994) Long-term persistence of zidovudine-resistance mutations in the plasma human immunodeficiency virus type 1 of didanosine-treated patients removed from zidovudine therapy. J Infect Dis 169: 184–188

    PubMed  Google Scholar 

  22. Soudeyns H, Yao X-J, Gao Q, Belleau B, Kraus J-L, Nguyen-Ba N, Spira B, Wainberg MA (1991) Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 35: 1386–1390

    PubMed  Google Scholar 

  23. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557–1559

    PubMed  Google Scholar 

  24. Yarchoan R, Broder S (1987) Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. N Engl J Med 316: 557–564

    PubMed  Google Scholar 

  25. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW, Shearea GM, Fischl MA, Mitsuya H, Gallo RC, Collins JM, Bolognesi DP, Myers CH, Broder S (1986) Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-IIIB/LAV replication, to patients with AIDS or AIDS-related complex. Lancet i: 575–580

    Google Scholar 

  26. Wainberg MA, Gu Z, Gao Q, Arts E, Geleziunas R, Bour S, Beaulieu R, Tsoukas C, Singer J, Montaner J (1993) Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr 6 [Suppl 1]: s36-s46

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lady Davis Institute — Jewish General Hospital and McGill University AIDS Centre, Montreal, Quebec, Canada

    Q. Gao, Z. Gu, H. Salomon, K. Nagai, M. A. Parniak & M. A. Wainberg

Authors
  1. Q. Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Salomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. A. Parniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. A. Wainberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, Q., Gu, Z., Salomon, H. et al. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. Archives of Virology 136, 111–122 (1994). https://doi.org/10.1007/BF01538821

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01538821

Keywords

Search

Navigation